Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Kidney cancer: combining PARP inhibitors and immunotherapy

Tracy Rose • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Kidney Cancer NKTR-214 Sitravatinib

Tracy Rose, MD, MPH, University of North Carolina, Chapel Hill, NC, discusses PARP inhibitors and new immunotherapy agents for metastatic renal cell carcinoma (RCC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Tracy Rose

1:21
Tracy Rose: RCC highlights
Tracy Rose • 13 Feb 2020
1:16
New tools for RCC treatment
Tracy Rose • 14 Feb 2020
2:53
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
Tracy Rose • 15 Feb 2019
4:10
Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427
Tracy Rose • 15 Feb 2019

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals